source
- FDA extends review of Capricor cell therapy; Pain drug startup to go publicThe agency is now reviewing an updated application for deramiocel with a “refined” indication. Elsewhere, a startup co-founded by Vivek Ramaswamy is taking a speedy path to the public markets.BioPharma Dive · 1h ago↗ source
- Qiagen appoints new chief executive after 9-month searchMolecular diagnostics specialist Qiagen has a new CEO as Jonathan M. Pratt takes the reins.Fierce Biotech · 6h ago↗ source
- US lawmakers push FDA to tighten rules on Chinese clinical data after three gene therapy deathsThree recent deaths in separate gene‑therapy trials in China have prompted two members of the U.S. House of Representatives to call on the FDA for new safeguards. Representatives John Moolenaar an…